Literature DB >> 24385076

Pre-treatment with new kynurenic acid amide dose-dependently prevents the nitroglycerine-induced neuronal activation and sensitization in cervical part of trigemino-cervical complex.

Annamária Fejes-Szabó1, Zsuzsanna Bohár, Enikő Vámos, Gábor Nagy-Grócz, Lilla Tar, Gábor Veres, Dénes Zádori, Márton Szentirmai, János Tajti, István Szatmári, Ferenc Fülöp, József Toldi, Árpád Párdutz, László Vécsei.   

Abstract

The systemic administration of nitroglycerine induces attacks in migraineurs and is able to activate and sensitize the trigeminal system in animals involving glutamate and α7-nicotinic acetylcholine receptors, among others. Kynurenic acid is one of the endogenous glutamate receptor antagonists, and exerts inhibitory action on the α7-nicotinic acetylcholine receptors. Since kynurenic acid penetrates the blood-brain barrier poorly, therefore a newly synthesized kynurenic acid amide, N-(2-N-pyrrolidinylethyl)-4-oxo-1H-quinoline-2-carboxamide hydrochloride (KYNAa) was used with such a side-chain substitution to facilitate brain penetration in our study. We evaluated its modulatory effect on kynurenic acid concentration in the cervical part of trigemino-cervical complex (C1-C2) and in the model of nitroglycerine-induced trigeminal activation using male Sprague-Dawley rats. One hour after 1 mmol/kg bodyweight KYNAa administration, the kynurenic acid level increased significantly in C1-C2, which returned to the basal level at 300 min measured by high-performance liquid chromatography. KYNAa pre-treatment had dose-dependent, mitigating action on nitroglycerine-induced decrease in calcitonin gene-related peptide and increase in c-Fos, neuronal nitric oxide synthase and calmodulin-dependent protein kinase II alpha expression in the C1-C2. KYNAa also mitigated the behavioural changes after nitroglycerine. Thus, in this model KYNAa is able to modulate in a dose-dependent manner the changes in neurochemical markers of activation and sensitization of the trigeminal system directly and indirectly--via forming kynurenic acid, possibly acting on peripheral and central glutamate or α7-nicotinic acetylcholine receptors. These results suggest that application of kynurenic acid derivatives could be a useful therapeutic strategy in migraine headache in the future with a different mechanism of action.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24385076     DOI: 10.1007/s00702-013-1146-2

Source DB:  PubMed          Journal:  J Neural Transm (Vienna)        ISSN: 0300-9564            Impact factor:   3.575


  64 in total

1.  Neuronal nicotinic acetylcholine receptors in rat trigeminal ganglia.

Authors:  L Liu; G Q Chang; Y Q Jiao; S A Simon
Journal:  Brain Res       Date:  1998-11-02       Impact factor: 3.252

2.  Endothelium-derived relaxing factor release on activation of NMDA receptors suggests role as intercellular messenger in the brain.

Authors:  J Garthwaite; S L Charles; R Chess-Williams
Journal:  Nature       Date:  1988-11-24       Impact factor: 49.962

Review 3.  Kynurenines, Parkinson's disease and other neurodegenerative disorders: preclinical and clinical studies.

Authors:  H Németh; J Toldi; L Vécsei
Journal:  J Neural Transm Suppl       Date:  2006

4.  Open-field bheavior in the rat: what does it mean?

Authors:  V H Denenberg
Journal:  Ann N Y Acad Sci       Date:  1969-07-30       Impact factor: 5.691

Review 5.  Kynurenines in the CNS: recent advances and new questions.

Authors:  László Vécsei; Levente Szalárdy; Ferenc Fülöp; József Toldi
Journal:  Nat Rev Drug Discov       Date:  2012-12-14       Impact factor: 84.694

6.  A glycine site associated with N-methyl-D-aspartic acid receptors: characterization and identification of a new class of antagonists.

Authors:  M Kessler; T Terramani; G Lynch; M Baudry
Journal:  J Neurochem       Date:  1989-04       Impact factor: 5.372

7.  Localization of nitric oxide synthase indicating a neural role for nitric oxide.

Authors:  D S Bredt; P M Hwang; S H Snyder
Journal:  Nature       Date:  1990-10-25       Impact factor: 49.962

8.  Modifications on the carboxylic function of kynurenic acid.

Authors:  Ferenc Fülöp; István Szatmári; József Toldi; László Vécsei
Journal:  J Neural Transm (Vienna)       Date:  2011-10-14       Impact factor: 3.575

9.  Spinal cord morphology and antinociception after chronic intrathecal administration of excitatory amino acid antagonists in the rat.

Authors:  Jens D Kristensen; Claes Post; Torsten Gordh; Björn A Svensson
Journal:  Pain       Date:  1993-09       Impact factor: 6.961

10.  The NMDA receptor antagonist MK-801 reduces capsaicin-induced c-fos expression within rat trigeminal nucleus caudalis.

Authors:  D D Mitsikostas; M Sanchez del Rio; C Waeber; M A Moskowitz; F M Cutrer
Journal:  Pain       Date:  1998-05       Impact factor: 6.961

View more
  11 in total

1.  Topical dura mater application of CFA induces enhanced expression of c-fos and glutamate in rat trigeminal nucleus caudalis: attenuated by KYNA derivate (SZR72).

Authors:  M Lukács; K Warfvinge; J Tajti; F Fülöp; J Toldi; L Vécsei; L Edvinsson
Journal:  J Headache Pain       Date:  2017-03-23       Impact factor: 7.277

Review 2.  Fathoming the kynurenine pathway in migraine: why understanding the enzymatic cascades is still critically important.

Authors:  Martina Curto; Luana Lionetto; Francesco Fazio; Dimos-Dimitrios Mitsikostas; Paolo Martelletti
Journal:  Intern Emerg Med       Date:  2015-02-24       Impact factor: 3.397

3.  Pathophysiological Mechanisms in Migraine and the Identification of New Therapeutic Targets.

Authors:  Kristian Agmund Haanes; Lars Edvinsson
Journal:  CNS Drugs       Date:  2019-06       Impact factor: 5.749

Review 4.  Migraine signaling pathways: amino acid metabolites that regulate migraine and predispose migraineurs to headache.

Authors:  Roger Gregory Biringer
Journal:  Mol Cell Biochem       Date:  2022-04-28       Impact factor: 3.842

5.  A comparative assessment of two kynurenic acid analogs in the formalin model of trigeminal activation: a behavioral, immunohistochemical and pharmacokinetic study.

Authors:  Gábor Veres; Annamária Fejes-Szabó; Dénes Zádori; Gábor Nagy-Grócz; Anna M László; Attila Bajtai; István Mándity; Márton Szentirmai; Zsuzsanna Bohár; Klaudia Laborc; István Szatmári; Ferenc Fülöp; László Vécsei; Árpád Párdutz
Journal:  J Neural Transm (Vienna)       Date:  2016-09-14       Impact factor: 3.575

Review 6.  Interactions between the Kynurenine and the Endocannabinoid System with Special Emphasis on Migraine.

Authors:  Gábor Nagy-Grócz; Ferenc Zádor; Szabolcs Dvorácskó; Zsuzsanna Bohár; Sándor Benyhe; Csaba Tömböly; Árpád Párdutz; László Vécsei
Journal:  Int J Mol Sci       Date:  2017-07-30       Impact factor: 5.923

7.  The Effect of Systemic Nitroglycerin Administration on the Kynurenine Pathway in the Rat.

Authors:  Gábor Nagy-Grócz; Klaudia F Laborc; Gábor Veres; Attila Bajtai; Zsuzsanna Bohár; Dénes Zádori; Annamária Fejes-Szabó; Eleonóra Spekker; László Vécsei; Árpád Párdutz
Journal:  Front Neurol       Date:  2017-06-14       Impact factor: 4.003

8.  Neurotransmitter and tryptophan metabolite concentration changes in the complete Freund's adjuvant model of orofacial pain.

Authors:  Edina K Cseh; Gábor Veres; Tamás Körtési; Helga Polyák; Nikolett Nánási; János Tajti; Árpád Párdutz; Péter Klivényi; László Vécsei; Dénes Zádori
Journal:  J Headache Pain       Date:  2020-04-21       Impact factor: 7.277

9.  Clinical relevance of depressed kynurenine pathway in episodic migraine patients: potential prognostic markers in the peripheral plasma during the interictal period.

Authors:  Bernadett Tuka; Aliz Nyári; Edina Katalin Cseh; Tamás Körtési; Dániel Veréb; Ferenc Tömösi; Gábor Kecskeméti; Tamás Janáky; János Tajti; László Vécsei
Journal:  J Headache Pain       Date:  2021-06-25       Impact factor: 7.277

10.  Kynurenic Acid Inhibits the Electrical Stimulation Induced Elevated Pituitary Adenylate Cyclase-Activating Polypeptide Expression in the TNC.

Authors:  Tamás Körtési; Bernadett Tuka; János Tajti; Teréz Bagoly; Ferenc Fülöp; Zsuzsanna Helyes; László Vécsei
Journal:  Front Neurol       Date:  2018-01-16       Impact factor: 4.003

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.